Posology: As the cardiovascular risks of etoricoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient's need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis (see Contraindications, Precautions, Adverse Reactions and Pharmacology: Pharmacokinetics under Actions).
Osteoarthritis: The recommended dose is 30 mg once daily. In some patients with insufficient relief from symptoms, an increased dose of 60 mg once daily may increase efficacy. In the absence of an increase in therapeutic benefit, other therapeutic options should be considered.
Rheumatoid arthritis: The recommended dose is 90 mg once daily.
Ankylosing spondylitis: The recommended dose is 90 mg once daily.
For acute pain conditions, etoricoxib should be used only for the acute symptomatic period.
Acute gouty arthritis: The recommended dose is 120 mg once daily. In clinical trials for acute gouty arthritis, etoricoxib was given for 8 days.
Postoperative dental surgery pain: The recommended dose is 90 mg once daily, limited to a maximum of 3 days. Some patients may require additional postoperative analgesia.
Doses greater than those recommended for each indication have either not demonstrated additional efficacy or have not been studied. Therefore: The dose for OA should not exceed 60 mg daily.
The dose for RA and ankylosing spondylitis should not exceed 90 mg daily.
The dose for acute gout should not exceed 120 mg daily, limited to a maximum of 8 days treatment.
The dose for postoperative acute dental surgery pain should not exceed 90 mg daily, limited to a maximum of 3 days.
Special populations: Elderly: No dose adjustment is necessary for elderly patients. As with other medicinal products, caution should be exercised in elderly patients (see Precautions).
Hepatic insufficiency: Regardless of indication, in patients with mild hepatic dysfunction (Child-Pugh score 5-6) a dose of 60 mg once daily should not be exceeded. In patients with moderate hepatic dysfunction (Child-Pugh score 7-9), regardless of indication, the dose of 60 mg every other day should not be exceeded; administration of 30 mg once daily can also be considered.
Clinical experience is limited particularly in patients with moderate hepatic dysfunction and caution is advised. There is no clinical experience in patients with severe hepatic dysfunction (Child-Pugh score ≥10); therefore, its use is contraindicated in these patients (see Contraindications, Precautions, and Pharmacology: Pharmacokinetics under Actions).
Renal insufficiency: No dose adjustment is necessary for patients with creatinine clearance ≥30 ml/min (see Pharmacology: Pharmacokinetics under Actions). The use of etoricoxib in patients with creatinine clearance <30 ml/min is contraindicated (see Contraindications and Precautions).
Paediatric patients: Etoricoxib is contraindicated in children and adolescents under 16 years of age (see Contraindications).
Method of administration: Etoricoxib is administered orally and may be taken with or without food. The onset of the effect of the medicinal product may be faster when etoricoxib is administered without food. This should be considered when rapid symptomatic relief is needed.